Clinical Research Directory
Browse clinical research sites, groups, and studies.
Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis
Sponsor: Belfast Health and Social Care Trust
Summary
Sepsis is a common and life-threatening condition caused by a dysregulated host immune response to infection. Given the prominent role of endothelial breakdown and dysfunction in sepsis, therefore, there is an urgent need to establish strategies to protect the endothelium and preserve microcirculatory function. This study is a randomised clinical study investigating intravenous fluid therapy and oral imatinib therapy in healthy human volunteers exposed to intravenous lipopolysaccharide (LPS). The objective of the study is to investigate the biological effects of fluid and imatinib therapy on LPS-induced microcirculatory dysfunction.
Key Details
Gender
All
Age Range
18 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
65
Start Date
2024-12-01
Completion Date
2026-07-01
Last Updated
2024-10-04
Healthy Volunteers
Yes
Interventions
Imatinib
Pre-treatment with 600mg Imatinib administered 1 hour prior to intravenous LPS.
Compound sodium lactate solution
Total of 30 ml/kg administered 90 minutes following intravenous LPS. 30mls/kg (maximum volume of 2500mls) administered in two divided doses (15mls/kg) intravenously. Each bolus will be administered at a fixed rate of 999mls/hr.